첫 페이지 News 본문

Securities Times E-Company News: Sanofi and Jixing Pharmaceutical announced today the signing of a formal agreement, which stipulates that Sanofi will acquire Jixing Pharmaceutical's exclusive rights to develop and commercialize Aficamten in Greater China. The transaction is expected to be completed within 2024, and the transaction amount is not publicly disclosed.
您需要登录后才可以回帖 登录 | Sign Up

本版积分规则

白云追月素 注册会员
  • Follow

    0

  • Following

    0

  • Articles

    39